NEW YORK and LONDON, January 3rd, 2017 Phase II trial in eculizumab resistant PNH expected to expand into US Akari Therapeutics (NASDAQ: AKTX), an …
PRESS RELEASES
Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins
NEW YORK and LONDON, December 5th, 2016 - Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing- -PAS-Coversin pre-clinical …
Akari Therapeutics to Attend Upcoming Investor Conferences In November
NEW YORK and LONDON, November 11th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today …
[Read more...] about Akari Therapeutics to Attend Upcoming Investor Conferences In November
